	2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	449	461	466	465	510	579	527	667	763	937	951	1,191	1,559	1,477	2,023
Cost of Operating Revenue	338	330	298	300	311	338	324	447	478	564	569	650	749	770	1,039
Gross Profit	110	131	167	165	199	241	204	220	285	373	382	541	810	706	984
Gross Margin	24.6	28.4	35.9	35.4	39.1	41.6	38.6	32.9	37.3	39.8	40.2	45.4	51.9	47.8	48.6
Total Operating Expenses	411	414	407	417	445	491	498	629	690	827	856	961	1,131	1,210	1,540
Operating Profit	37	47	59	48	65	88	29	38	72	110	95	230	427	267	483
Operating Margin	8.3	10.2	12.7	10.3	12.7	15.2	5.5	5.7	9.5	11.7	10.0	19.3	27.4	18.1	23.9
Financing Income/(Expense) - Net	-37	-33	-27	-27	-23	-21	-19	-18	-21	-18	-13	-22	-6	3	-24
Profit before Taxes	1	16	35	25	42	67	14	20	53	105	82	216	401	346	489
Income Taxes	-2	3	8	9	15	20	2	4	13	25	18	52	101	86	125
Profit after Tax	3	14	27	16	27	47	12	16	16	81	64	164	300	260	364
PAT Margin	0.6	3.0	5.8	3.4	5.4	8.1	2.3	2.5	2.1	8.6	6.7	13.7	19.3	17.6	18.0
EPS - Basic - ex Extraordinary Items	3.92	16.27	30.89	17.84	30.76	42.01	10.81	13.06	30.75	62.85	49.74	127.45	233.89	202.74	283.71
EPS - Diluted - ex Extraordinary Items	3.92	16.26	30.88	17.84	30.75	42.01	10.81	13.06	30.75	62.85	49.74	127.45	233.89	202.74	283.71
EBIT	37	47	59	48	65	88	29	38	72	110	95	230	427	267	483
EBITDA	52	62	74	63	80	107	51	64	104	149	144	283	487	332	574
EBITDA Margin	11.6	13.4	15.9	13.6	15.8	18.6	9.7	9.6	13.6	15.9	15.2	23.7	31.2	22.5	28.4

Balance Sheet

Abridged

Understanding Balance Sheet

Neuland Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	R 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	222	227	288	316	322	375	447	453	515	550	581	761	921	1,139	1,483
Long-Term Investments	10	7	7	7	10	33	33	33	33	19	20	20	20	2	14
Property Plant & Equipment - Net	178	171	165	164	189	175	290	335	365	431	487	498	569	718	1,102
Total Non-Current Assets	204	198	196	196	495	511	624	677	716	775	803	819	911	1,040	1,447
Total Assets	426	425	483	512	817	886	1,071	1,130	1,231	1,325	1,383	1,580	1,833	2,180	2,930
Total Current Liabilities	289	263	307	295	273	286	367	327	358	369	363	439	428	466	710
Long Term Debt	56	51	34	33	33	30	103	61	80	98	111	78	54	109	261
Total Non-Current Liabilities	61	62	52	55	44	54	146	104	163	170	180	147	122	189	345
Total Liabilities	349	325	359	350	317	340	513	431	521	538	543	586	550	655	1,056
Total Shareholders' Equity	76	100	124	161	500	546	558	699	710	786	841	994	1,283	1,525	1,874
Minority Interest	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Total Equity	76	100	124	162	500	546	558	699	710	786	841	994	1,283	1,525	1,874
Total Liabilities & Equity	426	425	483	512	817	886	1,071	1,130	1,231	1,325	1,383	1,580	1,833	2,180	2,930

Cash Flow

Abridged

Understanding Cash Flow Statement

Neuland Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	17.24	35.20	49.19	34.20	48.29	73.80	30.05	30.93	87.35	123.40	115.50	236.56	343.75	260.02	472.72
Working Capital - Increase/(Decrease)	4.72	-31.35	-16.82	-38.76	-19.46	-55.94	-40.02	15.47	-49.17	49.22	-67.58	-10.96	-88.74	58.27	-141.42
Net CF from Operating Activities	21.96	3.86	32.38	-4.57	28.83	17.86	-9.96	46.40	38.18	172.62	47.92	225.60	255.02	318.29	331.29
Capital Expenditures - Net	5.21	7.06	11.19	14.64	18.77	40.99	132.66	62.73	48.02	105.39	97.25	64.64	142.41	205.30	396.21
Net CF from Investing Activities	-5.21	-7.22	-10.12	-14.36	-20.15	-42.49	-117.30	-78.67	-53.89	-86.58	-96.60	-63.04	-157.58	-307.45	-432.34
Dividends Paid - Cash - Total	-	-	1.07	2.67	1.60	1.22	-	-	4.95	2.57	3.85	6.41	12.83	17.96	15.40
Stock - Issuance/(Retirement) - Net	-	2.25	0.10	25.02	-	0.04	-	124.51	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-16.34	-2.23	-21.32	-2.34	-5.73	22.29	127.10	-87.58	23.84	-92.20	55.13	-116.23	-42.40	51.30	60.37
Net Cash Flow from Financing Activities	-16.33	2.08	-22.29	19.12	-7.33	21.11	127.10	36.93	18.89	-94.76	51.28	-122.64	-55.23	33.34	44.97
Free Cash Flow to Equity	0.40	-5.43	-0.14	-21.54	4.33	-0.83	-15.53	-103.91	14.00	-24.97	5.80	44.73	70.21	164.30	-4.55
Free Operating CF net dividend	16.61	-10.31	19.44	-22.68	7.92	-24.48	-143.56	-16.72	-15.56	64.65	-53.62	153.05	98.52	93.87	-81.23
Free Operating CF	16.61	-10.31	20.51	-20.01	9.52	-23.26	-143.56	-16.72	-10.61	67.22	-49.77	159.47	111.35	111.83	-65.84

Business Segment Analysis

FY End:

Mar 25

Neuland Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacture of active pharmaceutical ingredients and allied services (100.0%)₹ 206.46 Cr

Revenue / Sales

Manufacture of active pharmaceutical ingredients and allied services (100.0%)₹ 1,476.84 Cr

Assets

Manufacture of active pharmaceutical ingredients and allied services (100.0%)₹ 2,179.88 Cr

Operating Income

Manufacture of active pharmaceutical ingredients and allied services (100.0%)₹ 266.58 Cr

Regional Segment Analysis

FY End:

Mar 25

Neuland Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (30.4%)₹ 435.90 CrEurope (29.9%)₹ 428.33 CrNorth America (29.3%)₹ 420.98 CrRest of the World (10.4%)₹ 149.17 Cr

Historical Segment Analysis

Track how Neuland Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacture of active pharmaceutical ingredients and allied services	49	105	96	66	144	206

Frequently Asked Questions

What is the revenue of Neuland Laboratories Ltd.?

The latest trailing twelve month revenue of Neuland Laboratories Ltd. is ₹ 2,022.99 Cr, reflecting a 1-year growth of 36.98% and a 3-year CAGR of 19.31%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Neuland Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Neuland Laboratories Ltd. is ₹ 364.00 Cr, with a 3-year earnings CAGR of 30.57%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Neuland Laboratories Ltd.?

The trailing twelve month EBITDA of Neuland Laboratories Ltd. is approximately ₹ 482.76 Cr (based on an operating margin of 23.86%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Neuland Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Neuland Laboratories Ltd. is 283.71. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Neuland Laboratories Ltd.?

The debt-to-equity ratio of Neuland Laboratories Ltd. stands at 0.16. The interest coverage ratio is 20.16x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Neuland Laboratories Ltd.?

The estimated book value per share of Neuland Laboratories Ltd. is 1,461.00 (derived from a P/B ratio of 12.93 and market price of ₹ 18,889.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Neuland Laboratories Ltd.?

The trailing twelve month operating cash flow of Neuland Laboratories Ltd. is ₹ 331.29 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Neuland Laboratories Ltd. report consolidated or standalone financials?

Neuland Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.